155 related articles for article (PubMed ID: 37671852)
1. Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience.
Caso JM; Fernández-Ruiz M; López-Medrano F; Caro-Teller JM; Lizasoain M; San-Juan R; Fayos Pérez M; Rodríguez-Goncer I; Silva JT; Aguado JM
J Med Virol; 2023 Sep; 95(9):e29082. PubMed ID: 37671852
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir.
Quah KSE; Huang X; Renia L; Oon HH
Ann Acad Med Singap; 2022 Dec; 51(12):774-786. PubMed ID: 36592146
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
[TBL] [Abstract][Full Text] [Related]
5. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
Ito W; Fukumori T; Asaoka N; Imakita N; Nishimura T; Furukawa R; Nishihara Y; Fujikura H; Sekine T; Yamaguchi N; Hirata Y; Miyamoto S; Kanno T; Katano H; Suzuki T; Kasahara K
J Infect Chemother; 2024 Jul; 30(7):659-663. PubMed ID: 38184107
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
[TBL] [Abstract][Full Text] [Related]
7. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
Lai CC; Hsueh PR
J Med Virol; 2023 Feb; 95(2):e28430. PubMed ID: 36571273
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study.
Basoulis D; Tsakanikas A; Gkoufa A; Bitsani A; Karamanakos G; Mastrogianni E; Georgakopoulou VE; Makrodimitri S; Voutsinas PM; Lamprou P; Kontos A; Tsiakas S; Gamaletsou MN; Marinaki S; Sipsas NV
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515201
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting.
Mutoh Y; Umemura T; Nishikawa T; Kondo K; Nishina Y; Soejima K; Noguchi Y; Bando T; Ota S; Shimahara T; Hirota S; Hagimoto S; Takei R; Fukihara J; Sasano H; Yamano Y; Yokoyama T; Kataoka K; Matsuda T; Kimura T; Ichihara T; Kondoh Y
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992519
[TBL] [Abstract][Full Text] [Related]
11. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.
Cha-Silva AS; Gavaghan MB; Bergroth T; Alexander-Parrish R; Yang J; Draica F; Patel J; Garner DA; Stanford RH; Meier G; McLaughlin JM; Nguyen JL
Am J Ther; 2024 May-Jun 01; 31(3):e246-e257. PubMed ID: 38691664
[TBL] [Abstract][Full Text] [Related]
13. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019.
Ganatra S; Dani SS; Ahmad J; Kumar A; Shah J; Abraham GM; McQuillen DP; Wachter RM; Sax PE
Clin Infect Dis; 2023 Feb; 76(4):563-572. PubMed ID: 35986628
[TBL] [Abstract][Full Text] [Related]
14. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
15. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19.
Wu JY; Liu MY; Liu TH; Chuang MH; Hsu WH; Huang PY; Tsai YW; Lai CC
Int J Antimicrob Agents; 2023 Dec; 62(6):106984. PubMed ID: 37769748
[TBL] [Abstract][Full Text] [Related]
16. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
Liu TH; Wu JY; Huang PY; Tsai YW; Lai CC
J Med Virol; 2023 Jul; 95(7):e28951. PubMed ID: 37436873
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
Liu TH; Huang PY; Wu JY; Chuang MH; Hsu WH; Tsai YW; Chang CC; Lai CC
J Med Virol; 2023 May; 95(5):e28801. PubMed ID: 37218308
[TBL] [Abstract][Full Text] [Related]
18. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
[TBL] [Abstract][Full Text] [Related]
19. Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross-sectional study of the National Covid Cohort Collaborative (N3C).
Xiao X; Mehta HB; Curran J; Garibaldi BT; Alexander GC;
Pharmacotherapy; 2023 Dec; 43(12):1251-1261. PubMed ID: 37539477
[TBL] [Abstract][Full Text] [Related]
20. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
